# Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer

> **NCT06714903** · — · RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 50 (estimated)

## Conditions studied

- Colorectal Neoplasms Malignant

## Interventions

- **OTHER:** treatment option-sintilimab plus fruquintinib
- **OTHER:** treatment option-fruquintinib alone

## Key facts

- **NCT ID:** NCT06714903
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06714903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06714903, "Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06714903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*